February 04, 2022

Acerta Pharma B.V. et al v. Sandoz Inc.

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. February 07, 2022

    AstraZeneca, Merck Want Calquence Generics Halted

    AstraZeneca and Merck have teamed up in Delaware to assert that MSN and Sandoz are infringing six patents with their proposed generic versions of the $500 million cancer drug Calquence.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS